Prescient Therapeutics Ltd (PTX):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Prescient Therapeutics Ltd (PTX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8000
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:31
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オーストラリア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Prescient Therapeutics Ltd (Prescient Therapeutics), formerly Virax Holdings Ltd, is a clinical stage oncology company that develops novel drugs for the treatment of solid and hematological cancers. The company’s lead drug candidate includes PTX-200, a potent small molecule inhibitor of the AKT pathway that is used in the development of various cancers, including ovarian and breast cancer as well as hematologic cancers such as acute myeloid leukemia; PTX-100, a drug that is used to kill cancer cells by blocking geranylgeranyl ransferase-1 (GGT-1). It develops immunotherapeutic products based on its Co-X-Gene technology platform. Prescient Therapeutics is headquartered in Melbourne, Victoria, Australia.

Prescient Therapeutics Ltd (PTX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Prescient Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Prescient Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Prescient Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Prescient Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Prescient Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Prescient Therapeutics Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Prescient Therapeutics Enter into Collaboration with US-Based Drug Development Company 10
Equity Offering 11
Prescient Therapeutics Raises USD3.8 Million in Second and Final Tranche of Private Placement of Shares 11
Prescient Therapeutics Raises USD1.3 Million in First Tranche of Private placement of Shares 12
Prescient Therapeutics to Raise USD2.5 Million in Rights Offering of Shares 13
Virax Announces Private Placement Of Shares For US$2.7 Million 14
Virax Completes Private Placement Of Units 15
Virax Announces Private Placement Of Shares For Up To US$2.3 Million 16
Acquisition 17
Virax Acquires Pathway Oncology 17
Virax Acquires AKTivate Therapeutics and TCN-P Cancer Drug 18
Prescient Therapeutics Ltd – Key Competitors 19
Prescient Therapeutics Ltd – Key Employees 20
Prescient Therapeutics Ltd – Locations And Subsidiaries 21
Head Office 21
Other Locations & Subsidiaries 21
Recent Developments 22
Product Approvals 22
Sep 04, 2017: Prescient to Resume Clinical Trial of PTX-200 in AML 22
May 01, 2017: FDA Grants Orphan Drug Designation for PTX-200 in Acute Myeloid Leukemia 23
Clinical Trials 24
Aug 30, 2018: Prescient Therapeutics: PTX-200 AML Study Expanded 24
Apr 10, 2018: PTX-200 Phase 1b Breast Cancer Trial Results Prescients Most Significant Clinical Milestone to Date 25
Dec 11, 2017: Prescient Therapeutics: Clinical Hold Lifted on PTX-200 Breast Cancer Trial 27
Nov 06, 2017: Prescient to Resume Clinical Trial of PTX-200 in Ovarian Cancer 28
May 29, 2017: Prescient Therapeutics Provides Update on Clinical Trials of PTX-200 29
Other Significant Developments 30
Jul 03, 2018: Prescient Therapeutics: PTXO Options Update 30
Appendix 31
Methodology 31
About GlobalData 31
Contact Us 31
Disclaimer 31

List of Tables
Prescient Therapeutics Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Prescient Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Prescient Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Prescient Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Prescient Therapeutics Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Prescient Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Prescient Therapeutics Enter into Collaboration with US-Based Drug Development Company 10
Prescient Therapeutics Raises USD3.8 Million in Second and Final Tranche of Private Placement of Shares 11
Prescient Therapeutics Raises USD1.3 Million in First Tranche of Private placement of Shares 12
Prescient Therapeutics to Raise USD2.5 Million in Rights Offering of Shares 13
Virax Announces Private Placement Of Shares For US$2.7 Million 14
Virax Completes Private Placement Of Units 15
Virax Announces Private Placement Of Shares For Up To US$2.3 Million 16
Virax Acquires Pathway Oncology 17
Virax Acquires AKTivate Therapeutics and TCN-P Cancer Drug 18
Prescient Therapeutics Ltd, Key Competitors 19
Prescient Therapeutics Ltd, Key Employees 20
Prescient Therapeutics Ltd, Subsidiaries 21

List of Figures
Prescient Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Prescient Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Prescient Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Prescient Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Prescient Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Prescient Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Prescient Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Prescient Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Prescient Therapeutics Ltd (PTX):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Ortivus AB (ORTI B):企業の財務・戦略的SWOT分析
    Summary Ortivus AB (Ortivus) is a supplier of mobile solutions for emergency medical care. The company develops and offers cardiology, and mobile monitoring and communication solutions. Its products portfolio comprises ortivus mobiMed software, ortivus M531 measuring unit, ortivus PM1-1 patient unit …
  • Bio Techne Corp (TECH)-医療機器分野:企業M&A・提携分析
    Summary Bio Techne Corp (Bio Techne), develops manufactures and sells biotechnology products and instruments for research and clinical diagnostics. The company provides proteins and antibodies, and related immunoassays and other reagents for research under brands such as R&D Systems, Novus, Biologic …
  • The Maryland Technology Development Corp:企業のM&A・事業提携・投資動向
    The Maryland Technology Development Corp - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's The Maryland Technology Development Corp Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed …
  • Rubis SCA (RUI):企業の財務・戦略的SWOT分析
    Rubis SCA (RUI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Royal DSM NV (DSM):企業の財務・戦略的SWOT分析
    Royal DSM NV (DSM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Premier Biomedical Inc (BIEI):製薬・医療:M&Aディール及び事業提携情報
    Summary Premier Biomedical Inc (Premier Biomedical) is a drug development company that develops medications for debilitating and fatal illnesses. The company offers Feldetrex, a drug candidate used for the treatment of multiple sclerosis, fibromyalgia, blood sepsis and viremia, and cancer. It develo …
  • Netalogue Technologies plc (NTLP):企業の財務・戦略的SWOT分析
    Summary Netalogue Technologies plc (Netalogue) is a technology company that develops, markets and support e-procurement software systems. The company offers services such as e-commerce solutions, web design, hosting and e-marketing. It solutions include B2B Webstores, B2B/C webstores, B2corp, B2chan …
  • Episurf Medical AB (EPIS B):企業の財務・戦略的SWOT分析
    Summary Episurf Medical AB (Episurf Medical), formerly Diamorph Medtech AB is a medical technology company that provides patient-specific treatments of painful joint injuries. It offers diagnosis and design of implants and surgical instruments. Its products include Episealer Femoral Twin, Episealer …
  • HSE Integrated Ltd:企業の戦略的SWOT分析
    HSE Integrated Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Kin and Carta plc (KCT):企業の財務・戦略的SWOT分析
    Kin and Carta plc (KCT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Eskom Holdings SOC Limited:企業の戦略・SWOT・財務情報
    Eskom Holdings SOC Limited - Strategy, SWOT and Corporate Finance Report Summary Eskom Holdings SOC Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Norwegian Air Shuttle ASA:戦略・SWOT・企業財務分析
    Norwegian Air Shuttle ASA - Strategy, SWOT and Corporate Finance Report Summary Norwegian Air Shuttle ASA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • E.ON SE Oil & Gas Exploration and Production Operations and Cost Analysis – 2017
    E.ON SE Oil & Gas Exploration and Production Operations and Cost Analysis - 2017 Summary E.ON SE(E.ON), formerly E.ON AG, is an energy company that generates electricity, produces, stores, transports and supplies gas, and conducts trading, carbon sourcing, and electricity and gas distribution. It ge …
  • T-System Inc-医療機器分野:企業M&A・提携分析
    Summary T-System Inc (T-System) is a healthcare service provider that offers clinical, financial, operational, and regulatory solutions. The company offers documentation solutions, which include EV, an emergency department information system; EV for physicians, a solution with ER-specific clinical c …
  • Centrais Eletricas Brasileiras S.A. (ELET6):電力:M&Aディール及び事業提携情報
    Summary Centrais Eletricas Brasileiras S.A. (Eletrobras) is an electric utility. It generates, transmits, and distributes energy. The company produces electricity from hydro, nuclear, wind, natural gas, oil, coal, solar, and biomass sources. Eletrobras promotes the Latin American electric integratio …
  • Cerenis Therapeutics Holding SA (CEREN):製薬・医療:M&Aディール及び事業提携情報
    Summary Cerenis Therapeutics Holding SA (Cerenis) is a biopharmaceutical company that discovers and develops HDL therapies for the treatment of cardiovascular and metabolic diseases. The company develops a portfolio of HDL therapies including HDL mimetics for the rapid regression of atherosclerotic …
  • Cascades Inc:戦略・SWOT・企業財務分析
    Cascades Inc - Strategy, SWOT and Corporate Finance Report Summary Cascades Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Astra Microwave Products Limited:企業の戦略・SWOT・財務情報
    Astra Microwave Products Limited - Strategy, SWOT and Corporate Finance Report Summary Astra Microwave Products Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Zeria Pharmaceutical Co Ltd (4559):企業の財務・戦略的SWOT分析
    Summary Zeria Pharmaceutical Co Ltd (Zeria), formerly Zeria Yakusho Kenkyusho Co Ltd is a pharmaceutical company that manufactures pharmaceutical and non-pharmaceuticals, veterinary pharmaceuticals, industrial chemicals and reagents. The company imports and exports healthcare products such as cosmet …
  • Ittehad Chemicals Ltd (ICL):企業の財務・戦略的SWOT分析
    Ittehad Chemicals Ltd (ICL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆